Clovis Oncology Inc. CLVS, -1.18% stock tumbled more than 14% in after-hours trading Friday after the company said it plans to discontinue the phase-two trial evaluating its rucaparib treatment in bladder cancer, according to a report. Clovis halted the trial due to the recommendation of an independent monitoring committee, according to Dow Jones. Clovis said the committee recommendation wasn’t a result of the “safety profile” of the treatment, according to Dow Jones.
Have breaking news sent to your inbox. Subscribe to MarketWatch’s free Bulletin emails. Sign up here.